{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:52:24Z","timestamp":1792479144832,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clgc.2025.102487","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T16:19:41Z","timestamp":1766247581000},"page":"102487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3416-3786","authenticated-orcid":false,"given":"Karine","family":"Tawagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4655-4426","authenticated-orcid":false,"given":"Ali R.","family":"Khaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka V.","family":"Chablani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6970-6509","authenticated-orcid":false,"given":"Jeannie","family":"Hoffman-Censits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2277-8668","authenticated-orcid":false,"given":"Vadim S.","family":"Koshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Plimack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt D.","family":"Galsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3965-3394","authenticated-orcid":false,"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter H.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clgc.2025.102487_bib0001","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","article-title":"Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up","volume":"34","author":"Balar","year":"2023","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.clgc.2025.102487_bib0002","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1200\/JCO.19.01213","article-title":"Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer","volume":"38","author":"Vuky","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102487_bib0003","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102487_bib0004","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.24.00340","article-title":"Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from checkmate 274","volume":"43","author":"Galsky","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102487_bib0005","doi-asserted-by":"crossref","first-page":"S1340","DOI":"10.1016\/j.annonc.2023.10.106","article-title":"LBA6 EV-302\/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV P) vs chemotherapy (chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC)","volume":"34","author":"Powles","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2025.102487_bib0006","doi-asserted-by":"crossref","first-page":"S1341","DOI":"10.1016\/j.annonc.2023.10.107","article-title":"LBA7 nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: results from the phase III CheckMate 901 trial","volume":"34","author":"Van der Heijden","year":"2023","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102487_bib0007","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN Guidelines\u00ae insights: bladder cancer, version 3.2024: featured updates to the NCCN guidelines","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.clgc.2025.102487_bib0008","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.euo.2025.01.003","article-title":"Implications and lessons from the withdrawal of sacituzumab govitecan for treating advanced urothelial carcinoma","volume":"8","author":"Benjamin","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102487_bib0009","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1200\/OP-24-00758","article-title":"Lines of therapy for locally advanced\/metastatic urothelial carcinoma: the new paradigm","volume":"21","author":"Abidoye","year":"2025","journal-title":"JCO Oncol Pract"},{"issue":"10397","key":"10.1016\/j.clgc.2025.102487_bib0010","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"The Lancet"},{"issue":"10460","key":"10.1016\/j.clgc.2025.102487_bib0011","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(24)01758-6","article-title":"Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 study","volume":"404","author":"Choueiri","year":"2024","journal-title":"The Lancet"},{"issue":"12","key":"10.1016\/j.clgc.2025.102487_bib0012","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.annonc.2021.08.2151","article-title":"Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer","volume":"32","author":"Schoenfeld","year":"2021","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102487_bib0013","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.eururo.2025.01.002","article-title":"Pembrolizumab retreatment: lessons from a selected group of patients with urothelial carcinoma","volume":"87","author":"Zugman","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102487_bib0014","series-title":"Drug sequencing, pairing, switching, and the role of checkpoint rechallenging","author":"O\u2019Donnell","year":"2024"},{"issue":"2","key":"10.1016\/j.clgc.2025.102487_bib0015","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clgc.2022.11.003","article-title":"Treatment rechallenge with immune checkpoint inhibitors in advanced urothelial carcinoma","volume":"21","author":"Makrakis","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2025.102487_bib0016","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005921","article-title":"Society for immunotherapy of cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors","volume":"11","author":"Kluger","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2025.102487_bib0017","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC immunotherapy resistance taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clgc.2025.102487_bib0018","series-title":"Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA","author":"Galsky","year":"2025"},{"key":"10.1016\/j.clgc.2025.102487_bib0019","doi-asserted-by":"crossref","first-page":"S1763","DOI":"10.1016\/j.annonc.2025.09.124","article-title":"LBA2 perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: the phase III KEYNOTE-905 study","volume":"36","author":"Vulsteke","year":"2025","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.clgc.2025.102487_bib0020","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.2217\/fon-2021-0273","article-title":"Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: phase III KEYNOTE-866 and KEYNOTE-905\/EV-303","volume":"17","author":"Galsky","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.clgc.2025.102487_bib0021","series-title":"A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D)+ tremelimumab (T)+ enfortumab vedotin (EV) or D+ EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC)(VOLGA)","author":"Powles","year":"2022"},{"issue":"5","key":"10.1016\/j.clgc.2025.102487_bib0022","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102487_bib0023","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","article-title":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102487_bib0024","series-title":"A phase III randomized trial of eribulin (E) with gemcitabine (G) vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD\/PDL1 antibody (Ab): SWOG S1937 updated design","author":"Sadeghi","year":"2024"},{"issue":"2","key":"10.1016\/j.clgc.2025.102487_bib0025","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-471924","article-title":"Unmet potential of antibody-drug conjugates: an evaluation of the past, present, and future of antibody-drug conjugate development in advanced urothelial carcinoma","volume":"45","author":"Zarrabi","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clgc.2025.102487_bib0026","series-title":"Treatment patterns and clinical outcomes with platinum-based chemotherapy after enfortumab vedotin and pembrolizumab in patients with metastatic urothelial carcinoma","author":"Sternschuss","year":"2025"},{"key":"10.1016\/j.clgc.2025.102487_bib0027","author":"Galsky","year":"2021"},{"issue":"1","key":"10.1016\/j.clgc.2025.102487_bib0028","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.annonc.2023.09.3114","article-title":"The double antibody drug conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma","volume":"35","author":"McGregor","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2025.102487_bib0029","series-title":"A phase 2\/3 study of Bicycle toxin conjugate BT8009 targeting nectin-4 in patients with locally advanced or metastatic urothelial cancer (la\/mUC): Duravelo-2","author":"Loriot","year":"2024"},{"key":"10.1016\/j.clgc.2025.102487_bib0030","doi-asserted-by":"crossref","first-page":"S1138","DOI":"10.1016\/j.annonc.2024.08.2052","article-title":"1967MO preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma (la\/mUC): RC48G001 cohort C","volume":"35","author":"Galsky","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2025.102487_bib0031","unstructured":"Sava J., First-Line Disitamab Vedotin\/Toripalimab Shows Benefit in HER2+ la\/mUC."},{"issue":"23","key":"10.1016\/j.clgc.2025.102487_bib0032","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","article-title":"Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer","volume":"393","author":"Sheng","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102487_bib0033","series-title":"Enfortumab vedotin plus pembrolizumab in the treatment of locally advanced or metastatic bladder cancer of variant histology: A phase II study","author":"Nazha","year":"2024"},{"issue":"6","key":"10.1016\/j.clgc.2025.102487_bib0034","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/cncr.34057","article-title":"Efficacy of enfortumab vedotin in advanced urothelial cancer: analysis from the urothelial cancer network to investigate therapeutic experiences (UNITE) study","volume":"128","author":"Koshkin","year":"2022","journal-title":"Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T20:28:56Z","timestamp":1771705736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325001879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1558767325001879"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102487","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102487","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102487"}}